Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.

Onco Targets Ther · 2014 · PMC3928465 · PMID 24611018

Europe PMC DOI

hedged sentences

0.0931

closest p · 1.9× alpha

0.0931

boldest claim

The sentences

a nonsignificant trendP =0.0931so close (0.05 < p ≤ 0.1)

There was a nonsignificant trend towards increased OS in the erlotinib treatment arm in the Asian subpopulation (HR 0.67, P =0.0931), which reached statistical significance in Asian patients with EGFR IHC- positive status (HR 0.53, P =0.0233).

also in 5,406 other papers

did not reach statistical significanceno p-value reported

Still, it is not clear whether all patients with nonprogressive disease should receive maintenance therapy, especially those with activating EGFR mutations, for the effect of erlotinib on OS did not reach statistical significance in these patients compared to patients with wild-type EGFR .

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.